1. Home
  2. Pharma & Healthcare
  3. Global Bivalent Human Papillomavirus Vaccine Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Global Bivalent Human Papillomavirus Vaccine Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Publication Month: Feb 2023 | No. of Pages: 95 Published By: Global Info Research
Single User License: US $ 3480
Corporate User License: US $ 6960

According to our (Global Info Research) latest study, the global Bivalent Human Papillomavirus Vaccine market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
This report is a detailed and comprehensive analysis for global Bivalent Human Papillomavirus Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Bivalent Human Papillomavirus Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2018-2029
Global Bivalent Human Papillomavirus Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2018-2029
Global Bivalent Human Papillomavirus Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2018-2029
Global Bivalent Human Papillomavirus Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Bivalent Human Papillomavirus Vaccine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Bivalent Human Papillomavirus Vaccine market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck & Co., Inc., GSK, INNOVAX, ZSSW and HUMANWELL HEALTHCARE, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Bivalent Human Papillomavirus Vaccine market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
HPV16
HPV18
Market segment by Application
9-16 Years Old
16-20 Years Old
20-26 Years Old
26-45 Years Old
Major players covered
Merck & Co., Inc.
GSK
INNOVAX
ZSSW
HUMANWELL HEALTHCARE
WALVAX
Serum Institute of India
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Bivalent Human Papillomavirus Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Bivalent Human Papillomavirus Vaccine, with price, sales, revenue and global market share of Bivalent Human Papillomavirus Vaccine from 2018 to 2023.
Chapter 3, the Bivalent Human Papillomavirus Vaccine competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Bivalent Human Papillomavirus Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Bivalent Human Papillomavirus Vaccine market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Bivalent Human Papillomavirus Vaccine.
Chapter 14 and 15, to describe Bivalent Human Papillomavirus Vaccine sales channel, distributors, customers, research findings and conclusion.

1 Market Overview
1.1 Product Overview and Scope of Bivalent Human Papillomavirus Vaccine
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Bivalent Human Papillomavirus Vaccine Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 HPV16
1.3.3 HPV18
1.4 Market Analysis by Application
1.4.1 Overview: Global Bivalent Human Papillomavirus Vaccine Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 9-16 Years Old
1.4.3 16-20 Years Old
1.4.4 20-26 Years Old
1.4.5 26-45 Years Old
1.5 Global Bivalent Human Papillomavirus Vaccine Market Size & Forecast
1.5.1 Global Bivalent Human Papillomavirus Vaccine Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Bivalent Human Papillomavirus Vaccine Sales Quantity (2018-2029)
1.5.3 Global Bivalent Human Papillomavirus Vaccine Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Merck & Co., Inc.
2.1.1 Merck & Co., Inc. Details
2.1.2 Merck & Co., Inc. Major Business
2.1.3 Merck & Co., Inc. Bivalent Human Papillomavirus Vaccine Product and Services
2.1.4 Merck & Co., Inc. Bivalent Human Papillomavirus Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Merck & Co., Inc. Recent Developments/Updates
2.2 GSK
2.2.1 GSK Details
2.2.2 GSK Major Business
2.2.3 GSK Bivalent Human Papillomavirus Vaccine Product and Services
2.2.4 GSK Bivalent Human Papillomavirus Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 GSK Recent Developments/Updates
2.3 INNOVAX
2.3.1 INNOVAX Details
2.3.2 INNOVAX Major Business
2.3.3 INNOVAX Bivalent Human Papillomavirus Vaccine Product and Services
2.3.4 INNOVAX Bivalent Human Papillomavirus Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 INNOVAX Recent Developments/Updates
2.4 ZSSW
2.4.1 ZSSW Details
2.4.2 ZSSW Major Business
2.4.3 ZSSW Bivalent Human Papillomavirus Vaccine Product and Services
2.4.4 ZSSW Bivalent Human Papillomavirus Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 ZSSW Recent Developments/Updates
2.5 HUMANWELL HEALTHCARE
2.5.1 HUMANWELL HEALTHCARE Details
2.5.2 HUMANWELL HEALTHCARE Major Business
2.5.3 HUMANWELL HEALTHCARE Bivalent Human Papillomavirus Vaccine Product and Services
2.5.4 HUMANWELL HEALTHCARE Bivalent Human Papillomavirus Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 HUMANWELL HEALTHCARE Recent Developments/Updates
2.6 WALVAX
2.6.1 WALVAX Details
2.6.2 WALVAX Major Business
2.6.3 WALVAX Bivalent Human Papillomavirus Vaccine Product and Services
2.6.4 WALVAX Bivalent Human Papillomavirus Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 WALVAX Recent Developments/Updates
2.7 Serum Institute of India
2.7.1 Serum Institute of India Details
2.7.2 Serum Institute of India Major Business
2.7.3 Serum Institute of India Bivalent Human Papillomavirus Vaccine Product and Services
2.7.4 Serum Institute of India Bivalent Human Papillomavirus Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Serum Institute of India Recent Developments/Updates
3 Competitive Environment: Bivalent Human Papillomavirus Vaccine by Manufacturer
3.1 Global Bivalent Human Papillomavirus Vaccine Sales Quantity by Manufacturer (2018-2023)
3.2 Global Bivalent Human Papillomavirus Vaccine Revenue by Manufacturer (2018-2023)
3.3 Global Bivalent Human Papillomavirus Vaccine Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Bivalent Human Papillomavirus Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Bivalent Human Papillomavirus Vaccine Manufacturer Market Share in 2022
3.4.2 Top 6 Bivalent Human Papillomavirus Vaccine Manufacturer Market Share in 2022
3.5 Bivalent Human Papillomavirus Vaccine Market: Overall Company Footprint Analysis
3.5.1 Bivalent Human Papillomavirus Vaccine Market: Region Footprint
3.5.2 Bivalent Human Papillomavirus Vaccine Market: Company Product Type Footprint
3.5.3 Bivalent Human Papillomavirus Vaccine Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Bivalent Human Papillomavirus Vaccine Market Size by Region
4.1.1 Global Bivalent Human Papillomavirus Vaccine Sales Quantity by Region (2018-2029)
4.1.2 Global Bivalent Human Papillomavirus Vaccine Consumption Value by Region (2018-2029)
4.1.3 Global Bivalent Human Papillomavirus Vaccine Average Price by Region (2018-2029)
4.2 North America Bivalent Human Papillomavirus Vaccine Consumption Value (2018-2029)
4.3 Europe Bivalent Human Papillomavirus Vaccine Consumption Value (2018-2029)
4.4 Asia-Pacific Bivalent Human Papillomavirus Vaccine Consumption Value (2018-2029)
4.5 South America Bivalent Human Papillomavirus Vaccine Consumption Value (2018-2029)
4.6 Middle East and Africa Bivalent Human Papillomavirus Vaccine Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Bivalent Human Papillomavirus Vaccine Sales Quantity by Type (2018-2029)
5.2 Global Bivalent Human Papillomavirus Vaccine Consumption Value by Type (2018-2029)
5.3 Global Bivalent Human Papillomavirus Vaccine Average Price by Type (2018-2029)
6 Market Segment by Application
6.1 Global Bivalent Human Papillomavirus Vaccine Sales Quantity by Application (2018-2029)
6.2 Global Bivalent Human Papillomavirus Vaccine Consumption Value by Application (2018-2029)
6.3 Global Bivalent Human Papillomavirus Vaccine Average Price by Application (2018-2029)
7 North America
7.1 North America Bivalent Human Papillomavirus Vaccine Sales Quantity by Type (2018-2029)
7.2 North America Bivalent Human Papillomavirus Vaccine Sales Quantity by Application (2018-2029)
7.3 North America Bivalent Human Papillomavirus Vaccine Market Size by Country
7.3.1 North America Bivalent Human Papillomavirus Vaccine Sales Quantity by Country (2018-2029)
7.3.2 North America Bivalent Human Papillomavirus Vaccine Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Bivalent Human Papillomavirus Vaccine Sales Quantity by Type (2018-2029)
8.2 Europe Bivalent Human Papillomavirus Vaccine Sales Quantity by Application (2018-2029)
8.3 Europe Bivalent Human Papillomavirus Vaccine Market Size by Country
8.3.1 Europe Bivalent Human Papillomavirus Vaccine Sales Quantity by Country (2018-2029)
8.3.2 Europe Bivalent Human Papillomavirus Vaccine Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Bivalent Human Papillomavirus Vaccine Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Bivalent Human Papillomavirus Vaccine Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific Bivalent Human Papillomavirus Vaccine Market Size by Region
9.3.1 Asia-Pacific Bivalent Human Papillomavirus Vaccine Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Bivalent Human Papillomavirus Vaccine Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Bivalent Human Papillomavirus Vaccine Sales Quantity by Type (2018-2029)
10.2 South America Bivalent Human Papillomavirus Vaccine Sales Quantity by Application (2018-2029)
10.3 South America Bivalent Human Papillomavirus Vaccine Market Size by Country
10.3.1 South America Bivalent Human Papillomavirus Vaccine Sales Quantity by Country (2018-2029)
10.3.2 South America Bivalent Human Papillomavirus Vaccine Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Bivalent Human Papillomavirus Vaccine Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Bivalent Human Papillomavirus Vaccine Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa Bivalent Human Papillomavirus Vaccine Market Size by Country
11.3.1 Middle East & Africa Bivalent Human Papillomavirus Vaccine Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Bivalent Human Papillomavirus Vaccine Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Bivalent Human Papillomavirus Vaccine Market Drivers
12.2 Bivalent Human Papillomavirus Vaccine Market Restraints
12.3 Bivalent Human Papillomavirus Vaccine Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Bivalent Human Papillomavirus Vaccine and Key Manufacturers
13.2 Manufacturing Costs Percentage of Bivalent Human Papillomavirus Vaccine
13.3 Bivalent Human Papillomavirus Vaccine Production Process
13.4 Bivalent Human Papillomavirus Vaccine Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Bivalent Human Papillomavirus Vaccine Typical Distributors
14.3 Bivalent Human Papillomavirus Vaccine Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer

Tables and Figures

List of Tables
Table 1. Global Bivalent Human Papillomavirus Vaccine Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Bivalent Human Papillomavirus Vaccine Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Merck & Co., Inc. Basic Information, Manufacturing Base and Competitors
Table 4. Merck & Co., Inc. Major Business
Table 5. Merck & Co., Inc. Bivalent Human Papillomavirus Vaccine Product and Services
Table 6. Merck & Co., Inc. Bivalent Human Papillomavirus Vaccine Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Merck & Co., Inc. Recent Developments/Updates
Table 8. GSK Basic Information, Manufacturing Base and Competitors
Table 9. GSK Major Business
Table 10. GSK Bivalent Human Papillomavirus Vaccine Product and Services
Table 11. GSK Bivalent Human Papillomavirus Vaccine Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. GSK Recent Developments/Updates
Table 13. INNOVAX Basic Information, Manufacturing Base and Competitors
Table 14. INNOVAX Major Business
Table 15. INNOVAX Bivalent Human Papillomavirus Vaccine Product and Services
Table 16. INNOVAX Bivalent Human Papillomavirus Vaccine Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. INNOVAX Recent Developments/Updates
Table 18. ZSSW Basic Information, Manufacturing Base and Competitors
Table 19. ZSSW Major Business
Table 20. ZSSW Bivalent Human Papillomavirus Vaccine Product and Services
Table 21. ZSSW Bivalent Human Papillomavirus Vaccine Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. ZSSW Recent Developments/Updates
Table 23. HUMANWELL HEALTHCARE Basic Information, Manufacturing Base and Competitors
Table 24. HUMANWELL HEALTHCARE Major Business
Table 25. HUMANWELL HEALTHCARE Bivalent Human Papillomavirus Vaccine Product and Services
Table 26. HUMANWELL HEALTHCARE Bivalent Human Papillomavirus Vaccine Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. HUMANWELL HEALTHCARE Recent Developments/Updates
Table 28. WALVAX Basic Information, Manufacturing Base and Competitors
Table 29. WALVAX Major Business
Table 30. WALVAX Bivalent Human Papillomavirus Vaccine Product and Services
Table 31. WALVAX Bivalent Human Papillomavirus Vaccine Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. WALVAX Recent Developments/Updates
Table 33. Serum Institute of India Basic Information, Manufacturing Base and Competitors
Table 34. Serum Institute of India Major Business
Table 35. Serum Institute of India Bivalent Human Papillomavirus Vaccine Product and Services
Table 36. Serum Institute of India Bivalent Human Papillomavirus Vaccine Sales Quantity (Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Serum Institute of India Recent Developments/Updates
Table 38. Global Bivalent Human Papillomavirus Vaccine Sales Quantity by Manufacturer (2018-2023) & (Units)
Table 39. Global Bivalent Human Papillomavirus Vaccine Revenue by Manufacturer (2018-2023) & (USD Million)
Table 40. Global Bivalent Human Papillomavirus Vaccine Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 41. Market Position of Manufacturers in Bivalent Human Papillomavirus Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 42. Head Office and Bivalent Human Papillomavirus Vaccine Production Site of Key Manufacturer
Table 43. Bivalent Human Papillomavirus Vaccine Market: Company Product Type Footprint
Table 44. Bivalent Human Papillomavirus Vaccine Market: Company Product Application Footprint
Table 45. Bivalent Human Papillomavirus Vaccine New Market Entrants and Barriers to Market Entry
Table 46. Bivalent Human Papillomavirus Vaccine Mergers, Acquisition, Agreements, and Collaborations
Table 47. Global Bivalent Human Papillomavirus Vaccine Sales Quantity by Region (2018-2023) & (Units)
Table 48. Global Bivalent Human Papillomavirus Vaccine Sales Quantity by Region (2024-2029) & (Units)
Table 49. Global Bivalent Human Papillomavirus Vaccine Consumption Value by Region (2018-2023) & (USD Million)
Table 50. Global Bivalent Human Papillomavirus Vaccine Consumption Value by Region (2024-2029) & (USD Million)
Table 51. Global Bivalent Human Papillomavirus Vaccine Average Price by Region (2018-2023) & (US$/Unit)
Table 52. Global Bivalent Human Papillomavirus Vaccine Average Price by Region (2024-2029) & (US$/Unit)
Table 53. Global Bivalent Human Papillomavirus Vaccine Sales Quantity by Type (2018-2023) & (Units)
Table 54. Global Bivalent Human Papillomavirus Vaccine Sales Quantity by Type (2024-2029) & (Units)
Table 55. Global Bivalent Human Papillomavirus Vaccine Consumption Value by Type (2018-2023) & (USD Million)
Table 56. Global Bivalent Human Papillomavirus Vaccine Consumption Value by Type (2024-2029) & (USD Million)
Table 57. Global Bivalent Human Papillomavirus Vaccine Average Price by Type (2018-2023) & (US$/Unit)
Table 58. Global Bivalent Human Papillomavirus Vaccine Average Price by Type (2024-2029) & (US$/Unit)
Table 59. Global Bivalent Human Papillomavirus Vaccine Sales Quantity by Application (2018-2023) & (Units)
Table 60. Global Bivalent Human Papillomavirus Vaccine Sales Quantity by Application (2024-2029) & (Units)
Table 61. Global Bivalent Human Papillomavirus Vaccine Consumption Value by Application (2018-2023) & (USD Million)
Table 62. Global Bivalent Human Papillomavirus Vaccine Consumption Value by Application (2024-2029) & (USD Million)
Table 63. Global Bivalent Human Papillomavirus Vaccine Average Price by Application (2018-2023) & (US$/Unit)
Table 64. Global Bivalent Human Papillomavirus Vaccine Average Price by Application (2024-2029) & (US$/Unit)
Table 65. North America Bivalent Human Papillomavirus Vaccine Sales Quantity by Type (2018-2023) & (Units)
Table 66. North America Bivalent Human Papillomavirus Vaccine Sales Quantity by Type (2024-2029) & (Units)
Table 67. North America Bivalent Human Papillomavirus Vaccine Sales Quantity by Application (2018-2023) & (Units)
Table 68. North America Bivalent Human Papillomavirus Vaccine Sales Quantity by Application (2024-2029) & (Units)
Table 69. North America Bivalent Human Papillomavirus Vaccine Sales Quantity by Country (2018-2023) & (Units)
Table 70. North America Bivalent Human Papillomavirus Vaccine Sales Quantity by Country (2024-2029) & (Units)
Table 71. North America Bivalent Human Papillomavirus Vaccine Consumption Value by Country (2018-2023) & (USD Million)
Table 72. North America Bivalent Human Papillomavirus Vaccine Consumption Value by Country (2024-2029) & (USD Million)
Table 73. Europe Bivalent Human Papillomavirus Vaccine Sales Quantity by Type (2018-2023) & (Units)
Table 74. Europe Bivalent Human Papillomavirus Vaccine Sales Quantity by Type (2024-2029) & (Units)
Table 75. Europe Bivalent Human Papillomavirus Vaccine Sales Quantity by Application (2018-2023) & (Units)
Table 76. Europe Bivalent Human Papillomavirus Vaccine Sales Quantity by Application (2024-2029) & (Units)
Table 77. Europe Bivalent Human Papillomavirus Vaccine Sales Quantity by Country (2018-2023) & (Units)
Table 78. Europe Bivalent Human Papillomavirus Vaccine Sales Quantity by Country (2024-2029) & (Units)
Table 79. Europe Bivalent Human Papillomavirus Vaccine Consumption Value by Country (2018-2023) & (USD Million)
Table 80. Europe Bivalent Human Papillomavirus Vaccine Consumption Value by Country (2024-2029) & (USD Million)
Table 81. Asia-Pacific Bivalent Human Papillomavirus Vaccine Sales Quantity by Type (2018-2023) & (Units)
Table 82. Asia-Pacific Bivalent Human Papillomavirus Vaccine Sales Quantity by Type (2024-2029) & (Units)
Table 83. Asia-Pacific Bivalent Human Papillomavirus Vaccine Sales Quantity by Application (2018-2023) & (Units)
Table 84. Asia-Pacific Bivalent Human Papillomavirus Vaccine Sales Quantity by Application (2024-2029) & (Units)
Table 85. Asia-Pacific Bivalent Human Papillomavirus Vaccine Sales Quantity by Region (2018-2023) & (Units)
Table 86. Asia-Pacific Bivalent Human Papillomavirus Vaccine Sales Quantity by Region (2024-2029) & (Units)
Table 87. Asia-Pacific Bivalent Human Papillomavirus Vaccine Consumption Value by Region (2018-2023) & (USD Million)
Table 88. Asia-Pacific Bivalent Human Papillomavirus Vaccine Consumption Value by Region (2024-2029) & (USD Million)
Table 89. South America Bivalent Human Papillomavirus Vaccine Sales Quantity by Type (2018-2023) & (Units)
Table 90. South America Bivalent Human Papillomavirus Vaccine Sales Quantity by Type (2024-2029) & (Units)
Table 91. South America Bivalent Human Papillomavirus Vaccine Sales Quantity by Application (2018-2023) & (Units)
Table 92. South America Bivalent Human Papillomavirus Vaccine Sales Quantity by Application (2024-2029) & (Units)
Table 93. South America Bivalent Human Papillomavirus Vaccine Sales Quantity by Country (2018-2023) & (Units)
Table 94. South America Bivalent Human Papillomavirus Vaccine Sales Quantity by Country (2024-2029) & (Units)
Table 95. South America Bivalent Human Papillomavirus Vaccine Consumption Value by Country (2018-2023) & (USD Million)
Table 96. South America Bivalent Human Papillomavirus Vaccine Consumption Value by Country (2024-2029) & (USD Million)
Table 97. Middle East & Africa Bivalent Human Papillomavirus Vaccine Sales Quantity by Type (2018-2023) & (Units)
Table 98. Middle East & Africa Bivalent Human Papillomavirus Vaccine Sales Quantity by Type (2024-2029) & (Units)
Table 99. Middle East & Africa Bivalent Human Papillomavirus Vaccine Sales Quantity by Application (2018-2023) & (Units)
Table 100. Middle East & Africa Bivalent Human Papillomavirus Vaccine Sales Quantity by Application (2024-2029) & (Units)
Table 101. Middle East & Africa Bivalent Human Papillomavirus Vaccine Sales Quantity by Region (2018-2023) & (Units)
Table 102. Middle East & Africa Bivalent Human Papillomavirus Vaccine Sales Quantity by Region (2024-2029) & (Units)
Table 103. Middle East & Africa Bivalent Human Papillomavirus Vaccine Consumption Value by Region (2018-2023) & (USD Million)
Table 104. Middle East & Africa Bivalent Human Papillomavirus Vaccine Consumption Value by Region (2024-2029) & (USD Million)
Table 105. Bivalent Human Papillomavirus Vaccine Raw Material
Table 106. Key Manufacturers of Bivalent Human Papillomavirus Vaccine Raw Materials
Table 107. Bivalent Human Papillomavirus Vaccine Typical Distributors
Table 108. Bivalent Human Papillomavirus Vaccine Typical Customers
List of Figures
Figure 1. Bivalent Human Papillomavirus Vaccine Picture
Figure 2. Global Bivalent Human Papillomavirus Vaccine Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Bivalent Human Papillomavirus Vaccine Consumption Value Market Share by Type in 2022
Figure 4. HPV16 Examples
Figure 5. HPV18 Examples
Figure 6. Global Bivalent Human Papillomavirus Vaccine Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 7. Global Bivalent Human Papillomavirus Vaccine Consumption Value Market Share by Application in 2022
Figure 8. 9-16 Years Old Examples
Figure 9. 16-20 Years Old Examples
Figure 10. 20-26 Years Old Examples
Figure 11. 26-45 Years Old Examples
Figure 12. Global Bivalent Human Papillomavirus Vaccine Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 13. Global Bivalent Human Papillomavirus Vaccine Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 14. Global Bivalent Human Papillomavirus Vaccine Sales Quantity (2018-2029) & (Units)
Figure 15. Global Bivalent Human Papillomavirus Vaccine Average Price (2018-2029) & (US$/Unit)
Figure 16. Global Bivalent Human Papillomavirus Vaccine Sales Quantity Market Share by Manufacturer in 2022
Figure 17. Global Bivalent Human Papillomavirus Vaccine Consumption Value Market Share by Manufacturer in 2022
Figure 18. Producer Shipments of Bivalent Human Papillomavirus Vaccine by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 19. Top 3 Bivalent Human Papillomavirus Vaccine Manufacturer (Consumption Value) Market Share in 2022
Figure 20. Top 6 Bivalent Human Papillomavirus Vaccine Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Global Bivalent Human Papillomavirus Vaccine Sales Quantity Market Share by Region (2018-2029)
Figure 22. Global Bivalent Human Papillomavirus Vaccine Consumption Value Market Share by Region (2018-2029)
Figure 23. North America Bivalent Human Papillomavirus Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 24. Europe Bivalent Human Papillomavirus Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 25. Asia-Pacific Bivalent Human Papillomavirus Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 26. South America Bivalent Human Papillomavirus Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 27. Middle East & Africa Bivalent Human Papillomavirus Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 28. Global Bivalent Human Papillomavirus Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 29. Global Bivalent Human Papillomavirus Vaccine Consumption Value Market Share by Type (2018-2029)
Figure 30. Global Bivalent Human Papillomavirus Vaccine Average Price by Type (2018-2029) & (US$/Unit)
Figure 31. Global Bivalent Human Papillomavirus Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 32. Global Bivalent Human Papillomavirus Vaccine Consumption Value Market Share by Application (2018-2029)
Figure 33. Global Bivalent Human Papillomavirus Vaccine Average Price by Application (2018-2029) & (US$/Unit)
Figure 34. North America Bivalent Human Papillomavirus Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 35. North America Bivalent Human Papillomavirus Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 36. North America Bivalent Human Papillomavirus Vaccine Sales Quantity Market Share by Country (2018-2029)
Figure 37. North America Bivalent Human Papillomavirus Vaccine Consumption Value Market Share by Country (2018-2029)
Figure 38. United States Bivalent Human Papillomavirus Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Canada Bivalent Human Papillomavirus Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Mexico Bivalent Human Papillomavirus Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Europe Bivalent Human Papillomavirus Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 42. Europe Bivalent Human Papillomavirus Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 43. Europe Bivalent Human Papillomavirus Vaccine Sales Quantity Market Share by Country (2018-2029)
Figure 44. Europe Bivalent Human Papillomavirus Vaccine Consumption Value Market Share by Country (2018-2029)
Figure 45. Germany Bivalent Human Papillomavirus Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. France Bivalent Human Papillomavirus Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. United Kingdom Bivalent Human Papillomavirus Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Russia Bivalent Human Papillomavirus Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Italy Bivalent Human Papillomavirus Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Asia-Pacific Bivalent Human Papillomavirus Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 51. Asia-Pacific Bivalent Human Papillomavirus Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 52. Asia-Pacific Bivalent Human Papillomavirus Vaccine Sales Quantity Market Share by Region (2018-2029)
Figure 53. Asia-Pacific Bivalent Human Papillomavirus Vaccine Consumption Value Market Share by Region (2018-2029)
Figure 54. China Bivalent Human Papillomavirus Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Japan Bivalent Human Papillomavirus Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Korea Bivalent Human Papillomavirus Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. India Bivalent Human Papillomavirus Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Southeast Asia Bivalent Human Papillomavirus Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Australia Bivalent Human Papillomavirus Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. South America Bivalent Human Papillomavirus Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 61. South America Bivalent Human Papillomavirus Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 62. South America Bivalent Human Papillomavirus Vaccine Sales Quantity Market Share by Country (2018-2029)
Figure 63. South America Bivalent Human Papillomavirus Vaccine Consumption Value Market Share by Country (2018-2029)
Figure 64. Brazil Bivalent Human Papillomavirus Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Argentina Bivalent Human Papillomavirus Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Middle East & Africa Bivalent Human Papillomavirus Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 67. Middle East & Africa Bivalent Human Papillomavirus Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 68. Middle East & Africa Bivalent Human Papillomavirus Vaccine Sales Quantity Market Share by Region (2018-2029)
Figure 69. Middle East & Africa Bivalent Human Papillomavirus Vaccine Consumption Value Market Share by Region (2018-2029)
Figure 70. Turkey Bivalent Human Papillomavirus Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Egypt Bivalent Human Papillomavirus Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Saudi Arabia Bivalent Human Papillomavirus Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. South Africa Bivalent Human Papillomavirus Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. Bivalent Human Papillomavirus Vaccine Market Drivers
Figure 75. Bivalent Human Papillomavirus Vaccine Market Restraints
Figure 76. Bivalent Human Papillomavirus Vaccine Market Trends
Figure 77. Porters Five Forces Analysis
Figure 78. Manufacturing Cost Structure Analysis of Bivalent Human Papillomavirus Vaccine in 2022
Figure 79. Manufacturing Process Analysis of Bivalent Human Papillomavirus Vaccine
Figure 80. Bivalent Human Papillomavirus Vaccine Industrial Chain
Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 82. Direct Channel Pros & Cons
Figure 83. Indirect Channel Pros & Cons
Figure 84. Methodology
Figure 85. Research Process and Data Source




Companies Mentioned
Merck & Co., Inc.
GSK
INNOVAX
ZSSW
HUMANWELL HEALTHCARE
WALVAX
Serum Institute of India

Reason to Buy

  • Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The segment that is expected to dominate the Pharma & Healthcare Market
  • Regions that are expected to witness the fastest growth during the forecast period
  • Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets